Copy to clipboard 
Corin announced the worldwide launch of the ApolloKnee surgical application and Apollo platform for robotic-assisted total knee replacement.
The ApolloKnee data-driven approach features three stages.
Plan: Comprehensively assess each patient’s knee balance with the pre-resection BalanceBot. The planning algorithm then presents an optimized surgical plan within the specified surgeon preferences.
Implement: The Apollo Robot, a compact, robotic cutting guide, supports precise and efficient bone resection. Control of the ApolloKnee workflow uses intraoperative gestures or a draped, touchscreen tablet.
Learn: Automatic data collection and cloud computing integrates pre-, intra- and post-operative information for continuous learning at every stage of the procedure.
The Apollo Robotic-Assisted Surgical platform and the ApolloKnee software application received FDA marketing clearance in late 2023, followed by approval under the CE Mark in 2024.
Beginning in February 2024, the limited market release of Apollo was structured to closely monitor the early clinical use and patient outcomes, while the manufacturing and supply chain established the scale for growth.
Feedback highlights also included the reliability of using a pre-resection knee balance assessment to plan the entire knee procedure, surgical efficiency provided by the gesture-controlled workflow and autonomous planning.
Corin’s vision for the future includes the development of additional software applications to further enhance the capabilities of the Apollo platform.
“Apollo and the ApolloKnee application now have regulatory clearance in all major markets and have successfully been used to objectively balance knees in more than 200 patients. This early success with Apollo is a testament to the dedication of our cross-functional teams, scalable manufacturing capability and strategic initial release.” said Jon Serbousek, CEO of Corin and Senior Advisor to private equity partner Permira.
Source: Corin
Corin announced the worldwide launch of the ApolloKnee surgical application and Apollo platform for robotic-assisted total knee replacement.
The ApolloKnee data-driven approach features three stages.
Plan: Comprehensively assess each patient's knee balance with the pre-resection BalanceBot. The planning algorithm then presents an optimized...
Corin announced the worldwide launch of the ApolloKnee surgical application and Apollo platform for robotic-assisted total knee replacement.
The ApolloKnee data-driven approach features three stages.
Plan: Comprehensively assess each patient’s knee balance with the pre-resection BalanceBot. The planning algorithm then presents an optimized surgical plan within the specified surgeon preferences.
Implement: The Apollo Robot, a compact, robotic cutting guide, supports precise and efficient bone resection. Control of the ApolloKnee workflow uses intraoperative gestures or a draped, touchscreen tablet.
Learn: Automatic data collection and cloud computing integrates pre-, intra- and post-operative information for continuous learning at every stage of the procedure.
The Apollo Robotic-Assisted Surgical platform and the ApolloKnee software application received FDA marketing clearance in late 2023, followed by approval under the CE Mark in 2024.
Beginning in February 2024, the limited market release of Apollo was structured to closely monitor the early clinical use and patient outcomes, while the manufacturing and supply chain established the scale for growth.
Feedback highlights also included the reliability of using a pre-resection knee balance assessment to plan the entire knee procedure, surgical efficiency provided by the gesture-controlled workflow and autonomous planning.
Corin’s vision for the future includes the development of additional software applications to further enhance the capabilities of the Apollo platform.
“Apollo and the ApolloKnee application now have regulatory clearance in all major markets and have successfully been used to objectively balance knees in more than 200 patients. This early success with Apollo is a testament to the dedication of our cross-functional teams, scalable manufacturing capability and strategic initial release.” said Jon Serbousek, CEO of Corin and Senior Advisor to private equity partner Permira.
Source: Corin
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
JV
Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.
